Background. Bilateral breast cancer (BBC) may present as synchronous (SBC) or metachronous breast cancer (MBC). Optimal surgical management of BBC patients is not well-defined. In this study, we report on histopathology, treatment, and outcomes in BBC patients. Methods. Upon Institutional Review Board approval, we identified BBC patients diagnosed and treated for invasive breast cancer between 1999 and 2007. Retrospective chart review for demographics, histopathology, treatment, and outcomes was performed, and factors associated with BCS choice were collected. Contraindication to BCS was defined as any of the following one-breast findings: multicentric disease, tumor considered too large for BCS, and a patient without a nominal breast size for acceptable cosmetic results. McNemar's test for matched pairs (binary variables) or the paired t test (continuous variables) were used to examine if a pathologic characteristic differed within a cancer pair. Kaplan-Meier methods estimated overall survival (OS). Results. A total of 203 BBC patients (119 SBC, 84 MBC) comprised our study group. Histopathologic characteristics of the first and second cancers diagnosed in both the SBC and MBC patients were very similar in histologic type and molecular profiles. Overall, 57 % of MBC patients underwent breast-conserving surgery (BCS) at initial diagnosis versus 34 % of patients with SBC. BCS contraindications were similar in both groups: 16 (34 %) MBC patients and 28 (36 %) SBC patients. Kaplan-Meier OS estimates at 5 and 10 years were 86 and 78 % for MBC, and 87 and 77 % for SBC patients, respectively. Conclusions. OS was excellent for both the MBC and SBC groups. Contraindications to BCS did not differ between groups. However, patients with SBC were less likely to undergo BCS compared with patients with MBC at the time of initial diagnosis.
Patients who are diagnosed with a primary breast cancer are at an increased risk of second primary breast cancers, 1 i.e., synchronous (SBC) or metachronous breast cancer (MBC). Although there are various definitions of SBC, the most common definition of SBC is a contralateral breast cancer diagnosed within 90 days of the first tumor. 2 Patients with MBC are thought to develop a second primary over the course of follow-up, usually defined as greater than 6 months from diagnosis of the first tumor. 3 Over the last 3 decades, in MBC patients, the incidence of a second primary cancer in the contralateral breast has been reported in various studies as ranging from 1.4 to 12.0 %, with 6-15 years of follow-up. [4] [5] [6] [7] The optimal surgical management of patients with bilateral breast cancer (BBC) is not well-defined. For patients with BBC who undergo breast-conserving surgery (BCS), the follow-up and risk of locoregional recurrence of each primary cancer, as well as the need for bilateral breast irradiation, may all be factors related to decision making. Similar outcomes have been reported with bilateral breast irradiation for BBC as for unilateral breast cancer. 8 In this study, we report on the pathologic findings, treatment, and outcomes of patients with BBC. We also sought to identify factors associated with choice of BCS.
METHODS

Institutional Review Board approval was obtained at
Memorial Sloan Kettering Cancer Center. A total of 203 BBC patients diagnosed and treated between 1999 and 2007 were identified from our prospectively maintained registered database of 10,629 patients reviewed during this time period. SBC was defined as an invasive BBC within 3 months of the initial diagnosis. In the SBC group, the right-sided cancer was designated as 'cancer 1' and the left-sided cancer was designated as 'cancer 2'. MBC was defined as an invasive BBC diagnosed C6 months from the initial diagnosis. In the MBC group, the initial cancer diagnosis was designated as 'cancer 1' and the contralateral cancer was reported as 'cancer 2'. Patients with a contralateral cancer diagnosed between 3 and 6 months after initial diagnosis were not included in this analysis in order to avoid misclassification between the two groups (n = 4).
Retrospective chart review was performed to identify patient demographics, histopathology, and treatment information. Family history of breast cancer in a first-or second-degree relative, BRCA mutation testing, and contraindications for BCS were identified and recorded. Contraindication to BCS was defined as any of the following findings in one breast: multicentric disease, a tumor considered too large for BCS, or a patient with a breast size too small for acceptable cosmetic results. We recorded instances in which the chart indicated patient choice as a primary reason for bilateral mastectomy in circumstances when the patient would have been a candidate for BCS or unilateral mastectomy.
Patient charts were reviewed for date of last follow-up and vital status. Location and date of recurrence were recorded for local/regional recurrence (index breast, contralateral breast, index axilla, or contralateral axilla) or distant metastasis. The locoregional and distant recurrences were calculated in each group.
Patient characteristics were summarized by whether a patient had MBC or SBC. Pathological characteristics were summarized for each cancer separately, and analyses compared each pair of cancers in patients with MBC and SBC separately. McNemar's test for matched pairs (binary variables) or the paired t test (continuous variables) were used to examine if a pathologic characteristic differed within a pair of cancers. Overall survival (OS) was estimated using Kaplan-Meier methods. Among MBC patients, OS was calculated from the time of diagnosis of the second cancer. Statistical analysis was performed using SAS (SAS Institute, Cary, NC, USA), and p values \0.05 were considered statistically significant.
RESULTS
Our study group consisted of 203 BBC patients: 119 with SBC, and 84 with MBC. Median age was 59 years (range 36-88) for the SBC patients and 52 years (range 31-80) for the MBC patients. Fifty-one (43 %) SBC patients had a family history of a first-or second-degree relative with breast cancer, and 35 (42 %) MBC patients had a family history of breast cancer. Thirty-six (18 %) patients underwent BRCA mutation testing. Of those tested, nine patients (25 %) tested positive for a BRCA mutation (five in BRCA1, four in BRCA2). Six of nine patients who were BRCA mutation carriers had bilateral mastectomies performed. Table 1 Table 2 shows pathologic findings for the cancers in both groups. The histopathologic characteristics of the first and second cancers diagnosed in each of the SBC and MBC patients revealed that they were very similar in both histologic type and molecular profiles [estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2)]. Table 3 shows the concordance within each group for cancer 1 and cancer 2 with respect to ER, PR, and HER2. The majority of patients in both groups had ER-positive breast cancer. Invasive ductal carcinoma was the most common histologic type for both cancers in our patients, and within each All data are expressed as n (%)
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor-2 a Concordance comparison was only performed on patients in whom ER, PR, and HER2 was known for both cancers Tables 1a and 1b ). The majority of BBC patients had negative axillary lymph nodes, absence of lymphovascular invasion, and unifocal tumors. We identified a small but significant difference in multifocality in the SBC group, with 35 and 21 % of first and second cancers being multifocal (p = 0.01). Table 4 provides treatment information for our patients. The surgical treatment for SBC and MBC differed. Fortyeight (57 %) patients with MBC had BCS at initial diagnosis compared with 34 % of patients with SBC. The majority of patients with SBC had a bilateral mastectomy (78 patients); of the remaining patients, 38 had bilateral BCS, and 3 had a mastectomy performed on one side and BCS on the contralateral side.
In both the MBC and SBC groups, patients were more likely to undergo axillary sentinel lymph node biopsy (SLNB) than an axillary lymph node dissection (ALND), and this is likely to reflect the period of time of our study, prior to SLNB becoming standard treatment.
Because more patients with MBC chose BCS with initial cancer diagnosis, they were also more likely to receive radiation therapy at diagnosis of their first cancer (p = 0.002). Table 2 shows the number of patients who received radiation therapy following lumpectomy and mastectomy by MBC and SBC groups. Patients with MBC were more likely to receive chemotherapy during treatment for their first cancer (p = 0.0004). There was no difference in hormonal treatment in either group. As expected, in the SBC group of patients, we saw uniformity of adjuvant treatment.
Of 84 MBC patients, 48 (57 %) had BCS at initial diagnosis and 40 (48 %) had BCS for their second cancer (p = 0.07). It is interesting to note that of the MBC patients who had undergone BCS at first cancer diagnosis, 18 (38 %) had bilateral mastectomy at the time of second diagnosis. It is unclear from chart review why these patients decided on bilateral mastectomy, given they were disease-free from the index cancer at the time of diagnosis of metachronous cancers.
We sought to identify whether there were contraindications to BCS in either group that would lead to the decision to proceed with mastectomy. Contraindications to unilateral BCS were similar in both groups: 16 (34 %) MBC patients and 28 (36 %) SBC patients, and not present in the majority of patients. Additionally, as mentioned previously, very few patients were tested for mutations in the BRCA genes. Of the 36 patients tested, only 9 had mutations, 6 of whom underwent bilateral mastectomy. We could not identify a contraindication to BCS in 43 % of the patients who chose bilateral mastectomy for surgical treatment. On chart review, patient choice was quoted as a primary decision-making factor, but it is likely that there were other reasons possibly beyond what we could discern from chart review.
The median interval between cancers in the MBC group was 2.5 years (range 0.3-6.3), while the median follow-up was 7.5 years (range 0.1-12.6) for the MBC group and 6.9 years (range 0.1-13.4) for the SBC group. Locoregional recurrences occurred in 16 (19 %) MBC patients (seven patients underwent BCS and nine patients underwent mastectomy) and six (5 %) SBC patients (one patient underwent BCS and five patients underwent mastectomy). Distant metastases occurred in 12 (14 %) MBC patients and 15 ( A secondary analysis for OS was performed based on ER concordant tumors and discordant tumors of the cancer in both groups. In the metachronous cancer group, 24 patients had discordant ER status and the concordant cases had better OS (p = 0.017), while in the synchronous group, 13 patients had discordant ER status and no significant difference in OS was noted (p = 0.73). Figure 1c shows OS for MBC patients, and Fig. 1d shows OS for SBC patients by ER concordant and discordant cases.
DISCUSSION
There is no general consensus on surgical treatment for patients with BBC. It has been suggested that therapy in BBC should resemble the treatment strategy in unilateral breast cancer. 9 Within the group of patients with BBC, the MBC and SBC groups presented at different times, likely affecting the choice of surgical treatment. Patients with SBC were faced with the diagnosis concurrently and, as our data show, they were more likely to have similar surgical treatment for both breasts.
The MBCs are more like unilateral breast cancers, as although all patients with primary breast cancer, have a risk of developing contralateral breast cancer, that risk is low overall. The latest overview of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B24 trial reported that with concurrent tamoxifen use, the risk of contralateral disease at 15 years follow-up was 7.3 %, 10 again demonstrating that BBC is an uncommon event.
Additionally, our MBC data are consistent with prior published reports indicating that the first cancer is often more advanced and larger than the contralateral (second) cancer. 11 Our patients with MBC had significantly largersize first tumors and were more likely to receive chemotherapy for the first diagnosis. This likely reflects the more advanced nature of the first cancer compared with the second cancer in MBC patients. Also, after MBC patients are diagnosed with their first breast cancer, they may undergo enhanced screening in the future, contributing to detecting a metachronous cancer at a smaller size and/or stage.
Of the MBC patients who had BCS (n = 48) at first cancer diagnosis, 18 (38 %) had bilateral mastectomy at the time of second diagnosis. It is unclear from chart review why these patients decided on bilateral mastectomy, given they were disease-free from the index cancer at the time of diagnosis of metachronous cancers, particularly as the metachronous tumors were smaller and multifocality did not significantly differ. Multiple reasons, including fear of having another diagnosis of breast cancer in the future, may have contributed to their decision. Concordance comparison was performed only on patients where ER status was known for both cancers. There were four patients in the MBC group and two patients in the SBC group, with one of the two cancers of unknown ER status that were excluded from the analysis. MBC metachronous breast cancer, SBC synchronous breast cancer, ER estrogen receptor, OS overall survival, CI confidence interval SBC patients were less likely to have BCS overall, and 66 % of SBC patients had a bilateral mastectomy at diagnosis. Very few SBC patients (three) had BCS surgery for one cancer and mastectomy for the other (contralateral) side. Contraindications to BCS did not differ between the MBC group compared with the SBC group, i.e. 34 versus 36 %. Overall, in our study group with BBC, 62 % underwent bilateral mastectomy. This included all patients who underwent bilateral mastectomy as the definitive surgery, including those who had bilateral mastectomy for treatment of MBC and those thought to have a reason why BCS could not be performed. Forty-four patients (35 %) had a contraindication that BCS was not selected in one breast and thus did not account for the high percentage of bilateral mastectomy. However, our data are consistent with other published reports, such as the study by Kheirelseid et al., who reported that 64.7 % of their BBC patients underwent bilateral mastectomy. 6 It is a limitation of our study, and beyond the scope of this retrospective study, to be able to fully identify all possible influential factors that are encompassed under surgical decision making, including patient choice. A further limitation of our study is that we did not have MRI data on all our patients, as this was not routinely used in the earlier years of our study period. Thus, as a result, we do not know the effect of this on patients.
It has been proposed that the diagnosis of two primary breast cancers may be the accumulation of genetic predisposition, or possibly two independent sporadic events.
12
BRCA1 and BRCA2 mutation carriers have an annual risk of 2-6 % of developing a second primary breast cancer. 13 In December 2013, the US Preventive Services Task Force recommended risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in those patients who may have an increased likelihood of a BRCA mutation. In addition to other factors, this also included those patients with BBC.
14 In our study, very few patients were tested for the BRCA genes, and only nine patients had a mutation identified, of whom six had bilateral mastectomy. It is likely that a fewer-than-expected number of BBC patients underwent BRCA mutation testing because our patients were diagnosed during an earlier time period when routine gene testing was not often offered to patients with BBC.
We noted that BBC patients had similar pathologic tumor characteristics of first and second cancers. This finding was also seen in a study by Baker et al. where no significant difference was observed between the first and second primary tumor in the study's SBC and MBC patients in terms of histologic features and hormonal status. 13 A more recent study by Huo et al. 15 found that, in the majority of cases, concordance in histological and biological parameters was noted between first and second cancers.
Similarly, a recent report using Surveillance, Epidemiology, and End Results (SEER) data found that among patients within SBC or MBC, pathologic tumor characteristics of the first and second cancer were likely to be the same. Discordant ER receptor status was found in 10 % of SBC patients and 14-15 % of MBC patients. However, the report noted that a discordance in ER of each cancer was an independent prognostic factor in each group. 16 In our study, the subset of patients who had discordant tumors comprised 13 patients in the SBC group and 24 patients in the MBC group (Table 3 ). An additional analysis showed that patients with a discordant ER receptor in the metachronous group had worse OS. This was not noted in the synchronous group; however, our analysis was limited by the few patients with discordant cancers in the SBC group.
Sandberg et al. also noted discordant ER adversely affected prognosis in SBC but not MBC. Interestingly, they noted MBC tumors that were concordant for ER-positive receptors had similar outcomes to concordant ER-negative tumors, thus raising the possibility of endocrine therapy resistance. 17 A limitation to studies on analysis of concordance is the inherent possibility of misclassification of hormone receptors that can occur between primary and secondary cancers. 18 It is a strength of our study that, being a singleinstitution study, the pathologic assessment was consistent for our patients.
Finally, its important to note that the prognosis of metachronous BBC is difficult to assess because it is conditional on the age of the patient and the survival of the patient after the first cancer diagnosis. 19 As reported by Diaz et al. in a retrospective study of 120 cases of BBC, there was no difference in OS between patients with SBC and the second diagnosis of MBC. 4 This was similar to the findings in our study where OS was similar in the MBC and SBC groups. Some studies show a trend toward decreased OS and local control for patients with SBC compared with either MBC or unilateral breast cancer, 5 while other studies, such as the study by Nichol et al., showed that in a matched analysis, breast cancer-specific survival was equivalent in SBC patients and unilateral breast cancer patients. 20 As recognized in other studies, analyzing OS in MBC and SBC patients together is biased, as the MBC patients have a survival advantage because they have lived long enough to develop the contralateral breast cancer. 21 Further limitations to our study include the small group of patients identified over a few decades, during which treatments may have varied. However, the small numbers of patients with BBC noted are consistent with published data. In a recent report by Londero et al., 22 a review of the published literature reveals the prevalence of MBC and SBC is low, at 3 and 7 %, respectively.
CONCLUSIONS
In patients with BBC, presenting with SBC led to a greater similarity in surgical treatment choice for both breasts, with the majority of patients choosing bilateral mastectomy. In patients with MBC, the majority of patients chose BCS at the time of initial diagnosis. Contraindications to BCS did not differ between the groups. In our study, although OS was similar in the MBC and SBC groups, patients in the MBC group with discordant ER receptor status had an overall worse prognosis.
